Instituto De Investigación Biomédica De Salamanca

This study tests a new treatment called TranspoCART19 for people with B-cell lymphoma that has come back or not responded to standard therapy. The treatment uses a patient's own immune cells, which are genetically modified to better recognize and attack cancer cells. The trial wi…

This Phase 3 trial tests whether giving higher doses of radiation twice a day can improve outcomes for people with limited-stage small cell lung cancer. All 300 participants will receive standard chemotherapy and be randomly assigned to one of three radiation dose levels. The stu…

This trial compares two doses of a dye called indocyanine green (ICG) given before laparoscopic gallbladder removal. The dye helps surgeons see the bile ducts clearly, which may reduce the risk of accidental injury. One group gets the standard dose hours before surgery; the other…

This study tests a new computer program that helps doctors diagnose blocked heart arteries more accurately using CT scans. The software combines several checks into one step, which may reduce the need for invasive procedures like heart catheterization. Researchers will look at pa…

This study tests whether a personalized 12-week exercise program, including aerobic, strength, balance, and flexibility training, can improve physical fitness and quality of life in adults aged 65 and older living in rural areas. Participants will be compared to a control group t…

This study looks at blood samples from 350 adults with blood cancer who develop a fever and have very low white blood cells (a condition called febrile neutropenia). The goal is to find patterns of proteins in the blood that can predict if a patient will develop serious complicat…

This study follows 400 adults with long COVID for four years to understand how the condition changes over time. Researchers will look at blood markers, blood vessel health, and fatigue levels. The goal is to find better ways to diagnose and manage long COVID in the future.

This study is enrolling 30 people with a common skin cancer called cutaneous squamous cell carcinoma who are about to start treatment with the immunotherapy drug cemiplimab. Researchers will use advanced lab techniques to analyze immune cells and molecules in participants' blood …